8-K: Pulse Biosciences Announces First U.S. Procedure with CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences has successfully completed the first U.S. procedure using its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation.

Summary

• Pulse Biosciences announced the first U.S. procedure using their CellFX nsPFA Percutaneous Electrode System.
• The procedure was performed at Sarasota Memorial Hospital on a patient with a large, symptomatic, benign thyroid nodule.
• The system received FDA 510(k) clearance in March 2024 for soft tissue ablation in percutaneous and intraoperative surgical procedures.
• The CellFX nsPFA system uses nanosecond pulsed field ablation to remove cellular tissue without damaging noncellular structures.
• The patient tolerated the procedure well with only local lidocaine and reported no pain during the energy delivery.
• A pilot program is underway to optimize and introduce the procedure throughout 2024.
• Previous procedures in Italy on 30 patients from April 2023 to January 2024 showed no evidence of scarring or injury to surrounding tissue.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the successful first U.S. procedure, FDA clearance, and promising results from previous studies. The technology appears to have significant potential, and the management's comments are optimistic.

Positives

• The CellFX nsPFA system allows for precise, non-thermal removal of cellular tissue.
• The procedure does not damage noncellular structures or induce thermal necrosis.
• The use of local anesthesia eliminates the need for general anesthesia in some cases.
• The system has the potential to set new standards for safety and efficacy.
• The procedure has the potential to decrease workflow time from patient set-up to procedure finish.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The success of early clinical procedures may not be predictive of the safety and efficacy of the device in all cases.
• Customer adoption and future use of the CellFX System are not guaranteed.

Future Outlook

Pulse Biosciences plans to continue optimizing and introducing the CellFX nsPFA percutaneous procedure on a controlled and measured basis throughout 2024, and is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets.

Management Comments

• Dr. Ralph P. Tufano stated that the cell-specific mechanism of action of nsPFA allowed him to treat the patient with confidence, knowing that he was not going to cause collateral damage to acellular structures.
• Mitch Levinson, Chief Strategy Officer of Pulse Biosciences, said that treating their first patient under their newly FDA-cleared nsPFA percutaneous system is a fundamental and opportune milestone.

Industry Context

This announcement highlights a significant step forward in the field of non-thermal tissue ablation, potentially offering a safer and more efficient alternative to traditional methods. The successful procedure and FDA clearance position Pulse Biosciences as a key player in the bioelectric medicine space.

Comparison to Industry Standards

• Traditional tissue ablation methods often involve thermal energy, which can cause damage to surrounding tissues. The CellFX nsPFA system offers a non-thermal alternative, potentially reducing complications and improving patient outcomes.
• Companies like Medtronic and Boston Scientific offer various ablation technologies, but Pulse Biosciences' nsPFA technology is unique in its approach to non-thermal cellular removal.
• The use of local anesthesia and the potential for decreased workflow time could give Pulse Biosciences a competitive advantage over other ablation methods that require general anesthesia and longer procedure times.

Stakeholder Impact

• Shareholders may view this announcement positively due to the successful milestone and potential for future growth.
• Patients may benefit from a safer and more effective treatment option for soft tissue ablation.
• Physicians may find the CellFX nsPFA system to be a valuable tool for treating various conditions.

Next Steps

• Pulse Biosciences will continue to optimize and introduce the CellFX nsPFA percutaneous procedure on a controlled and measured basis throughout 2024.
• The company will continue to develop its CellFX nsPFA technology for use in the treatment of atrial fibrillation and other markets.

Key Dates

Keywords

CellFX nsPFA, Percutaneous Electrode System, Nanosecond Pulsed Field Ablation, Soft Tissue Ablation, Thyroid Nodule, FDA 510(k), Non-thermal Ablation, Pulse Biosciences